The Effect of CAPD on the Lipid Profile of Pediatric Patients

Abstract

Get full access to this article

View all access options for this article.

References

K.W.

, Greene

E.L.

, Raij

Cardiovascular risk factors in chronic renal failure and hemodialysis populations.

Am J Kidney Dis 1992; 19: 505–13.

Attman

, Samuelsson

, Alaupovic

Lipoprotein metabolism and renal failure.

Am J Kidney Dis 1993; 21: 573–92.

Appel

Lipid abnormalities in renal disease.

Kidney Int 1991; 39: 169–83.

Keane

W.F.

Lipids and the kidney.

Kidney Int 1994; 46: 910–20.

Llopart

, Donate

, Oliva

J.A.

, Roda

, Rousaud

, Gonzalez–Sastre

Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients.

Nephrol Dial Transplant 1995; 10: 537–40.

Siamopoulos

K.C.

, Elisaf

M.S.

, Bairaktari

T.H.

, Pappas

M.B.

, Sferopoulos

G.D.

, Nikolakakis

N.G.

Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis.

Perit Dial Int 1995; 15: 342–7.

Avram

M.M.

, Sreedhara

, Patel

, Chattopadhyay

, Thu

, Fein

Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients?

Adv Perit Dial 1996; 12: 266–71.

Heimbürger

, Stenvinkel

, Berglund

, Tranæus

, Lindholm

Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.

Nephron 1996; 72: 135–44.

Webb

A.T.

, Reaveley

D.A.

, O'Donell

, O'Connor

, Seed

, Brown

E.A.

Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy.

Nephrol Dial Transplant 1995; 10: 354–7.

10.

Ramos

J.M.

, Heaton

, McGurk

J.G.

, Ward

M.K.

, Kerr

D.N.

Sequential changes in serum lipids and their sub-fractions in patients receiving continuous ambulatory peritoneal dialysis.

Nephron 1983; 35: 20–3.

11.

Breckenridge

W.C.

, Roncari

D.A.

, Khanna

, Oreopoulos

D.G.

The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins.

Atherosclerosis 1982; 45: 249–58.

12.

Querfeld

, Salusky

I.B.

, Nelson

, Foley

, Fine

R.N.

Hyperlipidemia in pediatric patients undergoing peritoneal dialysis.

Pediatr Nephrol 1988; 2: 447–52.

13.

Querfeld

, LeBoeuf

R.C.

, Salusky

I.B.

, Nelson

, Laidlaw

, Fine

R.N.

Lipoproteins in children treated with continuous peritoneal dialysis.

Pediatr Res 1991; 29: 155–9.

14.

Scolnik

, Balfe

J.W.

Initial hypoalbuminemia and hyperlipidemia persist during chronic peritoneal dialysis in children.

Perit Dial Int 1993; 13: 136–9.

15.

Querfeld

, Lang

, Friedrich

J.B.

, Kohl

, Fiehn

, Scharer

Lipoprotein (a) serum levels and apolipoprotein (a) phenotypes in children with chronic renal disease.

Pediatr Res 1993; 34: 772–6.

16.

Siamopoulos

K.C.

, Elisaf

Is CAPD atherogenic?

Perit Dial Int 1997; 17: 227–31.

17.

Wanner

, Lubrich–Birkner

, Summ

, Wieland

, Schollmeyer

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients.

Nephron 1992; 62: 40–6.

18.

Walker

R.J.

, Sutherland

W.H.

, Walker

H.L.

, MacMahon

, Robson

R.A.

Effect of treatment with simvastatin on serum cholesterol ester transfer in patients on dialysis.

Nephrol Dial Transplant 1997; 12: 87–92.

19.

Zwolinska

, Szprynger

Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis.

Przegl Lek 1997; 54: 320–3.

20.

Gidding

S.S.

, Stone

N.J.

, Bookstein

L.C.

, Laskarzewski

P.M.

, Stein

E.A.

Month to month variability of lipids, lipoproteins, and apolipoproteins and the impact of acute infection in adolescents.

J Pediatr 1998; 133: 242–6.